

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 2, 2017**

T2 BIOSYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

001-36571
(Commission
File Number)

20-4827488
(IRS Employer
Identification Number)

101 Hartwell Avenue, Lexington, Massachusetts 02421
(Address of principal executive offices, including Zip Code)

(781) 761-4646
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) The Annual Meeting of Stockholders of T2 Biosystems, Inc. (the "Company") occurred on June 2, 2017

(b) There were a total of 30,594,342 shares of the Company's common stock, par value \$0.001 per share, outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 27,554,441 shares of common stock were represented in person or by proxy; therefore, a quorum was present. The following proposals were submitted by the Board of Directors to a vote of the stockholders, each of which was approved by the requisite vote. The votes with respect to each proposal are set forth below.

1. **Proposal 1: Election of Class I Directors**

<u>Nominee</u>	<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
Stanley Lapidus	21,556,301	476,995	8,661	5,502,484

John W. Cumming	18,992,692	2,989,064	70,201	5,502,484
David Elsbree	21,500,788	480,653	70,516	5,502,484

Pursuant to the foregoing votes, the Class III Director nominees listed above were elected to serve on the Company's Board of Directors until the Company's 2020 Annual Meeting of Stockholders.

2. **Proposal 2: Ratification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm**

For:	27,413,441
Against:	111,059
Abstain:	29,941

Pursuant to the foregoing votes, the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2017 was ratified and approved.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 6, 2017

T2 BIOSYSTEMS, INC.

By: /s/ Darlene Deptula-Hicks
Darlene Deptula-Hicks
SVP and Chief Financial Officer